Ensuring Equitable Cancer Care for All Patients

By Sanjeev Arora, MD, MACP, FACC, and Ernest Hawk, MD, MPH

May 10, 2017

Cancer is the second-leading cause of death across the globe. Significant efforts, such as the National Cancer Moonshot Initiative and The University of Texas MD Anderson Cancer Center’s Moon Shots Program, will drive advances in cancer prevention, screening, and treatment. However, right now, these advances are not reaching everyone equally.

Gaps in knowledge transfer and access to high-quality care are significant contributors to inequity in healthcare access: the most vulnerable patients are simply unable to get the right care in the right place at the right time. With the help of our colleagues around the world, we hope to change that.

Recent data show that rural Americans are more likely to die of cancer than their urban counterparts. Only 3% of medical oncologists practice in rural areas, forcing these patients to travel great distances for care.

Further disparities in cancer care have developed in recent years, because advanced treatments are not accessible to all patients. For example, African American women in the United States die of breast cancer at a rate 40% higher than do non-Hispanic white women—a disparity that did not exist 3 decades ago. The situation is even worse in developing countries. For example, in Sub-Saharan Africa, the mortality rate for prostate cancer is more than double that in North America.

We believe Project ECHO is an important and powerful tool in the fight to end cancer—particularly in rural and underserved areas, where the capacity to provide high-quality care is limited. However, collaborators are essential for advancing this mission.

— Sanjeev Arora, MD, MACP, FACC, and Ernest Hawk, MD, MPH

Project ECHO

Project ECHO (Extension for Community Healthcare Outcomes) is an initiative that endeavors to increase best practice medical care to underserved people around the world and narrow these gaps in health care. With Project ECHO’s telementoring model of care, which pairs specialists at academic medical centers with primary care clinicians from rural and underserved areas throughout the United States and in other countries, physicians are able to deliver best-practice management of complex health conditions to patients in their communities. Developed in 2003 in New Mexico as a solution to a statewide crisis in hepatitis C, Project ECHO now works with 113 partners across the United States and 21 other countries on more than 55 different medical conditions.

A key innovation of Project ECHO is its Knowledge Networks, in which a multidisciplinary team of specialists shares their expertise and collaborates with numerous primary care teams to improve their capacity to deliver high-quality care in their communities. The “all teach, all learn” model increases access to specialty medical care in the patients’ communities without the need for additional providers or referrals to distant academic medical centers. Recently, the U.S. Senate and House of Representatives passed the ECHO Act to authorize further study of the impact of the ECHO model and how best to support its national expansion.

Network of Global Experts

As innovative cancer prevention, screening, and treatment approaches continue to evolve, we believe the ECHO model could be valuable across the entire cancer care spectrum. However, to realize the full potential of this model to promote greater equity in cancer care delivery, we must develop a multidisciplinary, collaborative network of global experts. We are pleased that MD Anderson Cancer Center will now serve as an ECHO superhub for oncology. Its mission will be to train new ECHO hubs focusing on cancer prevention, screening, care management, and survivorship.

Together with Project ECHO, in 2014, we established an oncology-focused ECHO program with a project aimed at improving cervical cancer prevention, screening, and management services in Texas’ Rio Grande Valley, an underserved region along the Texas–Mexico border. Due to poor health–care access and a paucity of local providers, cervical cancer rates in this region are as much as 30% higher than in the rest of the state.

Using the ECHO model, members of the MD Anderson faculty work with local providers to better educate women about the importance of cervical cancer screening and vaccination for the human papillomavirus. Our faculty members also mentor providers regarding best practices for managing abnormal screening results, including colposcopies, cervical biopsies, and loop electrosurgical excision procedures, to prevent cervical cancer.

Network of Global Experts

As innovative cancer prevention, screening, and treatment approaches continue to evolve, we believe the ECHO model could be valuable across the entire cancer care spectrum. However, to realize the full potential of this model to promote greater equity in cancer care delivery, we must develop a multidisciplinary, collaborative network of global experts. We are pleased that MD Anderson Cancer Center will now serve as an ECHO superhub for oncology. Its mission will be to train new ECHO hubs focusing on cancer prevention, screening, care management, and survivorship.

Together with Project ECHO, in 2014, we established an oncology-focused ECHO program with a project aimed at improving cervical cancer prevention, screening, and management services in Texas’ Rio Grande Valley, an underserved region along the Texas–Mexico border. Due to poor health–care access and a paucity of local providers, cervical cancer rates in this region are as much as 30% higher than in the rest of the state.

Using the ECHO model, members of the MD Anderson faculty work with local providers to better educate women about the importance of cervical cancer screening and vaccination for the human papillomavirus. Our faculty members also mentor providers regarding best practices for managing abnormal screening results, including colposcopies, cervical biopsies, and loop electrosurgical excision procedures, to prevent cervical cancer.

Through a number of successful partnerships, MD Anderson now works with local providers across Texas, Latin America, and Africa on projects focused on tobacco cessation, cancer survivorship, and palliative care, in addition to cancer prevention, screening, and care management. Moving forward, we envision a wide range of potential oncology–directed ECHO programs to train community health workers to provide prevention and wellness interventions, improve screening access, expand tumor boards, and share best practices from National Cancer Institute–designated cancer centers in the...
Ensuring Equitable Cancer Care for All Patients - The ASCO Post

areas of cancer care, palliation, and survivorship.

Partnering With Community Physicians

Local providers report that ECHO programs improve both their knowledge and ability to deliver high-quality care to their patients, but the benefits are not unidirectional. Each of these programs is part of a larger strategy to improve access and increase community-based clinical capacity while facilitating regular communication and stronger engagement of academic centers with local front-line providers.

ECHO telementoring sessions are the foundation upon which rewarding relationships that foster ongoing collaborative research and training projects are built. Regular communication allows us to better understand the unique challenges of providing care in underserved regions and to promote new models of care delivery while continuing to strengthen our relationships.

We believe Project ECHO is an important and powerful tool in the fight to end cancer—particularly in rural and underserved areas, where the capacity to provide high-quality care is limited. However, collaborators are essential for advancing this mission.

Therefore, we ask you, our colleagues, to share the specific needs in your communities that may provide opportunities to utilize the ECHO model and better deliver innovative prevention, screening, and treatment approaches to those who need them most. To learn more about starting a Project ECHO in your community, visit Project ECHO at http://echo.unm.edu.

Disclosure: Drs. Arora and Hawk reported no potential conflicts of interest.

References


Dr. Arora is Director of Project ECHO and Distinguished Professor of Medicine at the University of New Mexico Health Sciences Center in Albuquerque. Dr. Hawk is Vice President and Head of the Division of Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center in Houston.
ENSURING EQUITABLE CANCER CARE FOR ALL PATIENTS - THE ASCO POST

VITAL OPTIONS INTERNATIONAL INTRODUCES FREE eBOOK, THE CANCER CONCIERGE


PEMBROLIZUMAB IN SOLID TUMORS WITH MISMATCH-REPAIR DEFICIENCY

ASSOCIATION OF EGFR COPY NUMBER GAIN AND OUTCOME WITH GEFTINIB IN ADVANCED ESOPHAGEAL CANCER

ADDING ABEMACLIB TO FULVESTRAN IN HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

ONCOLOGIST BARBARA L. McANEY, MD, FASCO, MACP, ELECTED AMA PRESIDENT-ELECT

FIRST ANALYSIS OF A A C R PROJECT GENIE DATA PUBLISHED

ASCO 2017: SWOG CLINICAL TRIALS HAVE ADDED MORE THAN 3 MILLION YEARS OF LIFE FOR PATIENTS WITH CANCER

MOST READ STORIES

ASCO 2017: I-SPY 2 TRIAL: COMBINATION OF PEMBROLIZUMAB PLUS STANDARD NEOADJUVANT THERAPY IN HIGH-RISK BREAST CANCER

2017 GI CANCERS SYMPOSIUM: NIVOLUMAB DEMONSTRATED EFFICACY AND IMPROVED SURVIVAL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED GASTRIC CANCER

ASCO 2017: ALEX STUDY: ALCECTINIB HALTS LUNG CANCER GROWTH MORE THAN A YEAR LONGER THAN CRIZOTINIB

ASCO 2017: THE APHINITY TRIAL: ADDING A SECOND HER2 BLOCKER MAY LOWER CHANCE OF INVASIVE BREAST CANCER FOR SOME WOMEN

ASCO 2017: PREGNANCY AFTER BREAST CANCER DOES NOT INCREASE CHANCE OF RECURRENCE

ASCO 2016: 10 YEARS OF AROMATASE INHIBITOR THERAPY REDUCES BREAST CANCER RECURRENCE WITHOUT COMPROMISING QUALITY OF LIFE IN POSTMENOPAUSAL PATIENTS

ASCO 2017: THE IDEA COLLABORATION: GLOBAL STUDY SETS NEW RISK-BASED STANDARD TO PERSONALIZE CHEMOTHERAPY FOR COLON CANCER AFTER SURGERY

ALEX TRIAL: ALCETINIB VS CRIZOTINIB IN UNTREATED ADVANCED ALK-POSITIVE NSCLC

ASCO 2017: HIGHER GUT BACTERIA DIVERSITY TIED TO SLOWER METASTATIC MELANOMA PROGRESSION

ASCO 2017: LATITUDE TRIAL: ADDITION OF ABRIRATERONE TO STANDARD HORMONAL THERAPY IMPROVES OUTCOMES IN NEWLY DIAGNOSED METASTATIC PROSTATE CANCER

© 2016 HSP News Service, L.L.C.